NovoCure Ltd (NVCR) Actualités

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the...

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ノボキュア、2024年度第3四半期の決算を発表

四半期純収益は前年比22%増の1億5500万ドル、2024年9月30日時点で治療中の患者数は過去最高の4113人に FDAは転移性非小細胞肺がんの治療薬としてOptune Lua...

ノボキュア、クリストフ・ブラクマン氏を最高財務責任者（CFO）に任命

（ビジネスワイヤ） -- ノボキュア（NASDAQ：NVCR）は、クリストフ・ブラクマン氏を次期最高財務責任者（CFO）に任命したことを発表しました。ブラクマン氏...

Novocure ernennt Christoph Brackmann zum Finanzvorstand

Novocure (NASDAQ: NVCR) gab heute bekannt, dass Christoph Brackmann zum nächsten Finanzvorstand (CFO) des Unternehmens ernannt wurde. Christoph...

Form 8-K - Current report

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]